Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
Tom Martin,
Paul G Richardson,
Thierry Facon,
Philippe Moreau,
Aurore Perrot,
Ivan Spicka,
Kamlesh Bisht,
Marlene Inchauspé,
France Casca,
Sandrine Macé,
Helgi van de Velde,
Kenshi Suzuki
Affiliations
Tom Martin
UCSF Medical Center, San Francisco, CA
Paul G Richardson
Dana-Farber Cancer Institute, Boston, MA
Thierry Facon
Department of Haematology, Lille University Hospital, Lille
Philippe Moreau
Department of Hematology, University Hospital of Nantes, Nantes
Aurore Perrot
Centre Hospitalo-Universitaire (CHU) de Toulouse, Centre de Recherches en Cancérologie de Toulouse (CRCT), Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Université de Toulouse, UPS, Toulouse
Ivan Spicka
First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic
Kamlesh Bisht
Sanofi, Research and Development, Cambridge, MA
Marlene Inchauspé
IT-M Statistics for Sanofi, Neuilly sur-Seine
France Casca
IVIdata for Sanofi, Levallois-Perret
Sandrine Macé
Sanofi, Research and Development, Vitry-Sur-Seine
Helgi van de Velde
Sanofi, Research and Development, Cambridge, MA
Kenshi Suzuki
Department of Hematology, Japanese Red Cross Medical Center, Tokyo
